Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Intestinal Neoplasms 3Gastrointestinal Neoplasms 3Gastrointestinal Diseases 3Colorectal Neoplasms 3Rectal Neoplasms 2Digestive System Neoplasms 2Rectal Diseases 1Osteosarcoma 1Neoplasms by Site 1Neoplasms 1Intestinal Diseases 1Digestive System Diseases 1Colonic Neoplasms 1

Interventions

alvimopan 5Irinotecan 3Bevacizumab 3Leucovorin 2Fluorouracil 2repotrectinib 1pralsetinib 1napabucasin 1encorafenib 1alectinib 1Pemetrexed 1Oxaliplatin 1Ocoxin 1Levoleucovorin 1KRN-330 1Drug Therapy 1Cetuximab 1Capecitabine 15,10-methylenetetrahydrofolic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Intestinal Diseases × 5,10-methylenetetrahydrofolic acid × Clear all
NCT01397305 2020-09-09

An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

Isofol Medical AB

Phase 1/2 Completed
24 enrolled
Gastrointestinal

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Site, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡